CYP19A1 and polycystic ovary syndrome: The inducing drug inhibited aromatase, thereby increasing ovarian androgens, leading to hyperandrogenism, a hallmark of PCOS.[36] Similarly, we found a significant weight gain in letrozole treated PCO compared to control rats which was attributable to deposition of abdominal fat.[37, 38]